Investigating Serotonin Signalling in IBD Patients

Launched by MCMASTER UNIVERSITY · Jul 23, 2012

Keywords

ClinConnect Summary

This clinical trial is studying how changes in serotonin signaling might affect patients with Inflammatory Bowel Disease (IBD), which includes conditions like ulcerative colitis (UC) and Crohn's disease (CD). Researchers have noticed that patients with these conditions often have different levels of serotonin, a chemical that helps regulate gut function. The goal of this research is to better understand these alterations in serotonin signaling and how they relate to gastrointestinal (GI) inflammation.

To participate in the trial, individuals must be diagnosed with either Crohn's disease or ulcerative colitis, while healthy volunteers should not have any diagnosis of these diseases or irritable bowel syndrome. Participants will undergo assessments to help researchers gather information about their condition and treatment history. It's important to note that certain medications that affect serotonin or inflammation may exclude individuals from participating. Overall, this study aims to provide valuable insights into the role of serotonin in IBD, which could lead to improved treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient groups: Disease diagnosis (CD or UC),duration of disease, previous/type of treatments, duration of treatment and disease prognosis.
• • Healthy controls: No diagnosis of CD or UC and no diagnosis of IBS.
• Exclusion Criteria:
• • Patient groups: Drugs that directly affect components of 5-HT signaling, any other disease or condition that may interfere with study assessments as judged by the investigator.
• • Healthy controls:Chronic use of any anti-inflammatory drugs, drugs that directly affect components of 5-HT signalling and any other disease or condition that may interfere with study assessments as judged by the investigator.